GlaxoSmithKline‘s (NYSE:GSK) venture capital arm SR One has a new president.
Jens Eckstein will replace Christoph Westphal, who is leaving GSK at the end of the year to focus on business interests, including the Longwood Founder’s Fund, a venture capital fund that counts GSK among its investors.
London-based GSK has its U.S. headquarters in Research Triangle Park, North Carolina. SR One invests globally in emerging life sciences companies. Since 1985, SR One has invested more than $650 million in 140 companies. U.S. portfolio companies include Scynexis, an RTP-based drug discovery and development company that counts Merck (NYSE:MRK), Roche (OTC:RHHBY) and Sanofi-Aventis (NYSE:SNY) among its drug partners.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Eckstein is trained as a biochemist. He comes to SR One from TVM Capital where he has worked since 2004. As a general partner in that firm’s life sciences practice, he focused on early stage investments. Earlier this year, Eckstein became venture partner at TVM and was interim CEO and president of SelectX Pharmaceuticals. Before TVM Capital, Eckstein worked at Enanta Pharmaceuticals and Mitotix.
Eckstein will take his new post at SR One on Oct. 1 and reportto GSK’s R&D Chairman Moncef Slaoui. He will be based in Boston.